NOV 14, 2019 10:30 AM PST

Identifying the PIK3CA mutations that make a difference in breast cancer with the QIAGEN therascreen® PIK3CA RGQ PCR Kit

Sponsored by: QIAGEN
Speaker

Abstract

Breast cancer is the most frequently occurring form of cancer in women.  Whilst 5-year survival rates for localized disease approach 99%, cases of advanced breast cancer have a much poorer prognosis, with 5-year survival of around 27%.  Therefore, new treatment modalities for this indication are clearly welcome.  The Novartis drug PIQRAYTM (alpelisib) is the first -selective PI3Kinase inhibitor to be approved by the FDA for treatment of cases of advanced Hormone Receptor +ve / HER2 -ve breast cancer that also harbour activating mutations in the PIK3CA gene.  There are present in about 40% of cases, and therefore, it is necessary to use a companion diagnostic (CDx) test to identify patients eligible for treatment.  The therascreen PIK3CA RGQ PCR Kit is a rapid and reliable test, able to detect the presence of any of the 11 clinically actionable PIK3CA mutations in DNA from both FFPE tumor tissue and plasma specimens.  Clinically validated during the SOLAR-1 clinical trial, this test is currently the only FDA-approved CDx for this indication.  Available in the USA since May 2019, the Kit supports the delivery of precision medicine to patients for whom few other treatment options may remain.


Show Resources
You May Also Like
OCT 20, 2021 10:00 AM PDT
C.E. CREDITS
OCT 20, 2021 10:00 AM PDT
Date: October 20, 2021 Time:10:00am (PDT), 1:00pm (EDT) As the prevalence of Diabetes continues to rise in many areas across the globe, healthcare providers continue to look for methods that...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
NOV 30, 2021 10:00 AM PST
C.E. CREDITS
NOV 30, 2021 10:00 AM PST
Date: November 30, 2021 Time: 10:00am (PDT), 1:00pm (EDT) The prevalence of thyroid disease worldwide has served as a catalyst for healthcare providers to study various tools and methods to...
JUL 15, 2021 8:00 AM PDT
C.E. CREDITS
JUL 15, 2021 8:00 AM PDT
Date: July 15, 2021 Time: 8:00am (PDT), 11:00am (EDT) High dimensional full spectrum flow cytometry grants unprecedented access to previously unattainable parameters in cellular biology. Flu...
OCT 12, 2021 9:00 AM PDT
C.E. CREDITS
OCT 12, 2021 9:00 AM PDT
Date: October 12, 2021 Time: 9:00am (PDT), 12:00pm (EDT) SCIEX’s next-generation Biologics Explorer software is an innovative platform for the comprehensive and deep characterization o...
NOV 14, 2019 10:30 AM PST

Identifying the PIK3CA mutations that make a difference in breast cancer with the QIAGEN therascreen® PIK3CA RGQ PCR Kit

Sponsored by: QIAGEN


Show Resources
Loading Comments...
Show Resources